Pre-Targeting Bispecific Antibody (BSAB) and Pegylated Liposomal Drug Nanocarrier as Management of Acute Lymphoblastic Leukemia (ALL) In Pediatrics
Acute lymphoblastic leukemia (ALL) is a neoplastic condition commonly found in pediatric patients especially that involve B cell (B-ALL). Current treatments revolve around immunotherapy approaches such as Chimeric-Antigen Receptor T-cell (CAR-T) and tyrosine kinase inhibitor (TKI). However, flaws in both methods such as low pharmacokinetics, technical limitations, inability to recognize more than one antigen and other side effects remain a predicament to be solved. “immunotherapy”, “pediatry”, “b-all”, “bispesific antibody” and “PEGylated liposomal” were the keywords applied to scientific online databases, such as ScienceDirect, PubMed, dan Researchgate. A total of 25 journals were screened, reviewed and utilized with utmost precision to construct a literature review. Preparation of targeting bispesific antibody (BsAb) is constructed through the formation of chemical bond between the anti-mPEG scFV and CD20, whereas PEGylated liposomal drug nanocarriers is prepared through a covalent bonding chemical reaction. PEGylated drug nanocarriers has nontoxic, immunogenicity, antigenicity, and long half-life properties that increases both the pharmacokinetics and pharmacodynamics of anticancer drugs like chemotherapy through increased distribution, accumulation and decrease elimination of the drugs. BsAb will specifically target cancer-specific antigens, such as CD20 in cancer cells to initiate adaptive immune responses. Additionally, the antibody dependent endocytosis properties are a vital part in cancer therapy to increase cellular uptake of the liposome. All in all, the combination of bispesific antibody (BsAb) PEGylated liposomal drug nanocarriers towards B-ALL shows great promise towards the management of B-ALL in pediatric patients.
Aldoss, I., & Stein, A. S. (2018). Advances in adult acute lymphoblastic leukemia therapy. Leukemia & Lymphoma, 59(5), 1033–1050.
Alhallak, K., Sun, J., Wasden, K., Guenthner, N., O’Neal, J., Muz, B., King, J., Kohnen, D., Vij, R., & Achilefu, S. (2021). Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia, 35(8), 2346–2357.
Alshibani, E., AlShaibani, Z., & Al-Anazi, K. A. (2018). Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in the Era of Novel Therapies. Stem Cells in Clinical Practice and Tissue Engineering, 159.
Brinkmann, U., & Kontermann, R. E. (2017). The making of bispecific antibodies. MAbs, 9(2), 182–212. https://doi.org/10.1080/19420862.2016.1268307
Coccaro, N., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2019). Next-generation sequencing in acute lymphoblastic leukemia. International Journal of Molecular Sciences, 20(12), 2929.
Cornelison, M., Jabbour, E. J., & Welch, M. A. (2012). Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. Journal of Supportive Oncology, 10(1), 14–23.
Foà, R., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Puzzolo, M.-C., Canichella, M., Viero, P., Ferrara, F., & Lunghi, M. (2020). Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. New England Journal of Medicine, 383(17), 1613–1623.
Hunger, S. P., & Mullighan, C. G. (2015). Acute lymphoblastic leukemia in children. New England Journal of Medicine, 373(16), 1541–1552.
King, A. C., Pappacena, J. J., Tallman, M. S., Park, J. H., & Geyer, M. B. (2019). Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia Research, 79, 27–33.
Li, L., & Wang, Y. (2020). Recent updates for antibody therapy for acute lymphoblastic leukemia. Experimental Hematology and Oncology, 9(1), 1–11. https://doi.org/10.1186/s40164-020-00189-9
Li, X., & Chen, W. (2019). Mechanisms of failure of chimeric antigen receptor T-cell therapy. Current Opinion in Hematology, 26(6), 427–433.
Liu, Y.-F., Wang, B.-Y., Zhang, W.-N., Huang, J.-Y., Li, B.-S., Zhang, M., Jiang, L., Li, J.-F., Wang, M.-J., & Dai, Y.-J. (2016). Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine, 8, 173–183.
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., & Myers, G. D. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448.
Paul, S., Kantarjian, H., & Jabbour, E. J. (2016). Adult acute lymphoblastic leukemia. Mayo Clinic Proceedings, 91(11), 1645–1666.
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018). CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Current Hematologic Malignancy Reports, 13, 396–406.
Perdana, A. B., Saputra, F., & Aisyi, M. (2020). Update on diagnosis of childhood acute lymphoblastic leukemia (ALL) in Indonesia. Indonesian Journal of Cancer, 14(4), 115–116.
Terwilliger, T., & Abdul-Hay, M. (2017). Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal, 7(6), e577–e577.
Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., & Betenbaugh, M. J. (2019). Design and Production of Bispecific Antibodies. Antibodies, 8(3), 43. https://doi.org/10.3390/antib8030043
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017). New development in CAR-T cell therapy. Journal of Hematology & Oncology, 10, 1–11.
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y. U., & Tu, S. (2019). Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Frontiers in Immunology, 10, 2664.
Copyright (c) 2025 Viona Mareska, Wilson Halim, Gede Krishna Arim Sadeva
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
